Description

The Piroxicam-beta-cyclodextrincomplex (CAS No. 96684-39-8) is a pharmaceutical-grade inclusion complex formed between piroxicam, a potent nonsteroidal anti-inflammatory drug (NSAID), and beta-cyclodextrin, a cyclic oligosaccharide known for enhancing solubility and bioavailability. This complex is characterized by the molecular formula C₅₇H₈₃N₃O₃₉S, ensuring high purity and stability for research and formulation applications. The inclusion of piroxicam within the beta-cyclodextrin cavity improves its dissolution rate, making it ideal for oral and topical formulations targeting inflammation and pain management. This product is rigorously tested for compliance with pharmacopeial standards, ensuring reproducibility and reliability for scientific and industrial use.

Properties

• CAS Number: 96684-39-8
• Complexity: 2090
• IUPAC Name: 5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol;4-hydroxy-2-methyl-1,1-dioxo-N-(2-pyridyl)-1lambda6,2-benzothiazine-3-carboxamide
• InChI: InChI=1S/C42H70O35.C15H13N3O4S/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51;1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h8-63H,1-7H2;2-9,19H,1H3,(H,16,17,20)
• InChI Key: LBPBSKKEZXLVBQ-UHFFFAOYSA-N
• Exact Mass: 1465.4324410
• Molecular Formula: C57H83N3O39S
• Molecular Weight: 1466.3
• SMILES: CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3.C(C1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(O2)C(C8O)O)CO)CO)CO)CO)CO)CO)O)O)O
• Topological: 662
• Monoisotopic Mass: 1465.4324410
• Synonyms: Piroxicam-beta-cyclodextrincomplex, 96684-39-8, b-Cyclodextrin, compd. with4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide1,1-dioxide (1:1)OTHER CA INDEX NAMES:2H-1,2-Benzothiazine-3-carboxamide,4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide, compd. withb-cyclodextrin (1:1), Piroxicam-|A-cyclodextrincomplex, BCP10841, AS-84271, 4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1??,2-benzothiazine-3-carboxamide; 5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.2(3),?.2?,(1)(1).2(1)(3),(1)?.2(1)?,(2)(1).2(2)(3),(2)?.2(2)?,(3)(1)]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol, 5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol;4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide

The Piroxicam-beta-cyclodextrincomplex is primarily used in pharmaceutical research to develop enhanced drug delivery systems, particularly for improving the solubility and bioavailability of piroxicam. It is also employed in preclinical studies for anti-inflammatory and analgesic formulations. This complex is suitable for exploring novel oral or topical delivery mechanisms in therapeutic applications.

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.